Business
Metabolic diseases oral delivery licence signed
Metabolic diseases oral delivery licence signed.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n \n \n \n Poolbeg Pharma plc\n \n \n \n \n \n \n \n Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases\n \n \n \n \n \n \n \n \n \n Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023\n \n \n \n \n Prof Brendan Buckley joins Poolbeg's Scientific Advisory Board to guide clinical development of technology\n \n \n \n \n Licence expands Poolbeg's existing exclusive licence to AnaBio's oral vaccine delivery technology\n \n \n \n \n Investor Meet Company presentation on 14 December 2022 at 5:30pm\n \n \n \n \n \n \n \n \n Poolbeg Pharma\n \n \n (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading infectious disease focused biopharmaceutical company, announces that it has acquired an exclusive licence from InsuCaps Limited (\"InsuCaps\"), a sister company of AnaBio Technologies (\"AnaBio\"), to use InsuCaps' patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome related diseases including obesity, pre-diabetes and diabetes. Obesity alone costs the US healthcare system c. $173bn a year.\n \n \n \n \n \n Following the licence, in H1 2023 Poolbeg will rapidly commence a proof-of-technology clinical trial to determine that a Glucagon-like Peptide 1 receptor (GLP-1) agonist can be safely delivered orally in humans. GLP-1 agonists, which are used to treat diabetes and obesity, represent an extremely large, fast-growing opportunity estimated to grow to c.$22bn per annum by 2025. At present, all but one GLP-1 products are injectables, which are more onerous for patients than oral delivery.\n \n \n \n \n \n The upcoming trial is designed to provide data confirming that the patented microencapsulation and nanoencapsulation technologies can safely deliver GLP-1 orally, with results expected to be announced later next year. In line with its rapid-partnering model, Poolbeg then intends to licence the technology to pharma and biotech for use in obesity and / or diabetes, as well as other active molecules in metabolic syndrome related diseases.\n \n \n \n \n \n This oral GLP-1clinical trial rapidly follows the completion of Poolbeg's LPS challenge trial for POLB 001 and, like the LPS challenge study, is in line with Poolbeg's efficient, capital light approach to ...